Cynvenio Biosystems
Cynvenio, St. Luke's Partner on Breast Cancer Study
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Cynvenio Signs International Distribution Agreements for Liquid Biopsy Tests
While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.
The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
Cynvenio, Color to Offer Combined Hereditary and Somatic Cancer Blood Test
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.